Amryt Pharma (AMYT.L, AMYT LN)
AMRYT PHARMA HAS CONFIRMED THAT IT INTENDS TO ACQUIRE AEGERION PHARMACEUTICALS. THIS TRANSACTION IS SUBJECT TO PARTS OF THE TAKEOVER CODE, UNDER WHICH DAVY IS DEEMED TO BE AN ASSOCIATED PARTY. DAVY HAS THEREFORE DISCONTINUED THE PUBLICATION OF RESEARCH AND FORECAST INFORMATION AT THIS TIME. Formed in 2015, Amryt Pharma acquires, develops and commercialises therapies for orphan (rare) diseases, diseases that have small rates of prevalence among country populations. Amryt is not involved in drug discovery but acquires its pipeline through the acquisition and in-licensing of orphan therapies. The company currently has four assets in its portfolio (AP101, AP102, AP103 and Lojuxta) that are targeting multiple orphan indications. These therapies span both development and commercial stages of the lifecycle. Amryt also reports modest revenues from Imlan, the company's derma-cosmetics range of products. Imlan is considered a non-core part of the company's portfolio.
|Legal & General Group||5.2|
|Hargreaves Lansdown Mgmt||3.2|